BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Allow Innovative Progressions To have a Tremendous Effect - 2Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- 3Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- 4Former Peruvian President Pedro Castillo sentenced for conspiracy
- 5The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- Figure out how to Consolidate a Brain science Certificate with Social Work
- UN rights chief says Israeli policy in West Bank 'resembles apartheid system'
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- Vote In favor of Your Favored Shades
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- More parents refusing this shot that prevents serious bleeding at birth
- Pick Your Favored kind of soup
- Nine in 10 German industrial firms expect Iran war to hit business
